Opdualag(relatlimab)
Opdualag (relatlimab) is an antibody pharmaceutical. Relatlimab was first approved as Opdualag on 2022-03-18. It is used to treat melanoma in the USA. It has been approved in Europe to treat melanoma. The pharmaceutical is active against lymphocyte activation gene 3 protein.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Combinations
Opdualag
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Nivolumab
+
Relatlimab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Opdualag | nivolumab and relatlimab-rmbw | Bristol Myers Squibb | N-761234 RX | 2022-03-18 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| opdualag | Biologic Licensing Application | 2024-03-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| non-small-cell lung carcinoma | — | D002289 | — |
| lymphoma | — | D008223 | C85.9 |
| urinary bladder neoplasms | — | D001749 | C67 |
| melanoma | — | D008545 | — |
| kidney neoplasms | EFO_0003865 | D007680 | C64 |
| squamous cell carcinoma | — | D002294 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
nivolumab / relatlimab, Opdualag, Bristol-Myers Squibb Company | |||
| 2029-03-18 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9298 | Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg |
Clinical
Clinical Trials
99 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | — | — | 7 | 18 | 7 | — | 4 | 33 |
| Neoplasms | D009369 | — | C80 | 10 | 13 | 1 | — | 1 | 20 |
| Colorectal neoplasms | D015179 | — | — | 1 | 4 | 1 | — | — | 6 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 3 | 1 | — | — | 5 |
| Cutaneous malignant melanoma | D000096142 | — | — | 1 | 3 | 2 | — | — | 5 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | 3 | 1 | — | — | 4 |
| Invasive hydatidiform mole | D002820 | — | D39.2 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 5 | — | — | — | 6 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 3 | 3 | — | — | — | 5 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 3 | 3 | — | — | — | 5 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | 3 | — | — | — | 5 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | 3 | — | — | — | 4 |
| Recurrence | D012008 | — | — | 2 | 3 | — | — | — | 4 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | 3 | — | — | — | 4 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 3 | 1 | — | — | — | 4 |
| Glioblastoma | D005909 | EFO_0000515 | — | 2 | 2 | — | — | — | 4 |
| Uveal neoplasms | D014604 | EFO_1001230 | — | 1 | 3 | — | — | — | 4 |
Show 63 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gliosarcoma | D018316 | — | — | 1 | — | — | — | — | 1 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Motor activity | D009043 | EFO_0003940 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocarditis | D009205 | — | I51.4 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Relatlimab |
| INN | relatlimab |
| Description | Relatlimab is a monoclonal antibody designed for the treatment of melanoma. It is used in combination with nivolumab to treat melanoma.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3990044 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB14851 |
| UNII ID | AF75XOF6W3 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Opdualag – Bristol Myers Squibb
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,188 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
774 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use